MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
272.45
+2.81
+1.04%
After Hours: 272.35 -0.1 -0.04% 19:10 12/01 EST
OPEN
269.97
PREV CLOSE
269.64
HIGH
272.59
LOW
267.62
VOLUME
2.30M
TURNOVER
0
52 WEEK HIGH
288.46
52 WEEK LOW
208.37
MARKET CAP
145.81B
P/E (TTM)
19.37
1D
5D
1M
3M
1Y
5Y
Pfizer hits new 52-week low after weight loss setback
Pfizer shares hit new 52-week low after weight loss setback. Pfizer's twice-daily oral weight loss candidate danuglipron will not reach late-stage development. The company's first obesity candidate, lotiglipron, met a similar fate in june.
Seeking Alpha · 17h ago
Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed
Arrowhead pharmaceuticals reported positive preclinical toxicology results for aro-rage and aro-mmp7. The company reported fiscal q4 2023 results and provided a pipeline update this week. Shares of arrowhead dropped a quarter this week after fiscal q3 2023. Balance sheet concerns are weighing on the stock and the company needs to address them.
Seeking Alpha · 21h ago
‘From Hype to Clinical‘: Cowen Suggests 2 AI Healthcare Stocks to Consider
TipRanks · 22h ago
Pfizer pulls back from twice-daily regime of weight-loss drug candidate
Pfizer's weight-loss drug candidate met primary endpoint in a phase 2b clinical trial. Danuglipron met the primary endpoint of the study. Pfizer says twice-daily formulation of the drug will not advance into phase 3 studies. Shares of pfizer fell around 4% premarket.
Seeking Alpha · 23h ago
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
NASDAQ · 1d ago
Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.
Eli lilly and novo nordisk are leaders in the market for treating obesity plus diabetes. Obesity is one of the biggest commercial drug opportunities ever, analysts say. Obesity meds could be worth $67 billion in annual sales by 2032, barclays says. Amgen, pfizer and others are also developing obesity drugs.
Barron‘s · 1d ago
Looking Into Amgen's Recent Short Interest
Amgen's short percent of float has risen 5.83% since its last report. The company has 6.77 million shares sold short, which is 1.27% of all regular shares. Short interest is the number of shares that have been sold short but not yet covered.
Benzinga · 1d ago
The Zacks Analyst Blog Highlights McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software
NASDAQ · 1d ago
More
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.

Webull offers Amgen, Inc. stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.